Stock Under $10 with 50-100% upside potential - 14 Days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Threshold Pharmaceuticals Inc. (THLD): Today's Featured Drugs Winner

Threshold Pharmaceuticals (THLD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.3%. By the end of trading, Threshold Pharmaceuticals rose 26 cents (3.8%) to $7.20 on average volume. Throughout the day, 2.8 million shares of Threshold Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock ranged in a price between $6.68-$7.32 after having opened the day at $6.88 as compared to the previous trading day's close of $6.94. Other companies within the Drugs industry that increased today were: AspenBio Pharma (APPY), up 21.9%, Zogenix (ZGNX), up 15.7%, Ampio Pharmaceuticals (AMPE), up 11.7%, and Opexa Therapeutics (OPXA), up 8.9%.

Threshold Pharmaceuticals, Inc., a development stage company, focuses on the discovery and development of drugs for the microenvironment of solid tumors and the bone marrows of hematologic malignancies as novel treatments for patients living with cancer. Threshold Pharmaceuticals has a market cap of $370.6 million and is part of the health care sector. Shares are up 468.9% year to date as of the close of trading on Tuesday. Currently there are three analysts that rate Threshold Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Threshold Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

On the negative front, iBio (IBIO), down 13.2%, Rosetta Genomics (ROSG), down 11.8%, Complete Genomics (GNOM), down 11.5%, and Medgenics (MDGN), down 10.3%, were all losers within the drugs industry with Pfizer (PFE) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs